Does phlebotomy in people with haemochromatosis become history?

In The Lancet Gastroenterology & Hepatology, the results of a proof-of-concept trial by Kris V Kowdley and colleagues 1 Kowdley KV Modi NB Peltekian K et al. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023; (published online Oct 17.)https://doi.org/10.1016/S2468-1253(23)00250-9 Summary Full Text Full Text PDF Scopus (1) Google Scholar suggest that rusfertide, a peptidic hepcidin mimetic, was a safe and efficacious treatment for iron overload in patients on maintenance phlebotomies for HFE-related haemochromatosis. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trialRusfertide prevents iron re-accumulation in the absence of phlebotomies and could be a viable therapeutic option for selected patients with haemochromatosis. Full-Text PDF